Cedars-Sinai Cancer in Los Angeles serves one of the most diverse regions globally. Ranked No. 7 for cancer by U.S. News & World Report 2020-2021, the center’s clinicians are committed to providing compassionate, state-of-the-art care, while its scientists are carrying out the latest translational research and groundbreaking advances. The cancer enterprise includes the Samuel Oschin Comprehensive Cancer Institute, The Angeles Clinic and Research Institute, Tower Hematology Oncology Medical Group, Torrance Memorial Hunt Cancer Center and Cedars-Sinai Tarzana.
Immunotherapy-Based Endeavors Could Alter Treatment Landscape in Metastatic TNBC
Yuan Yuan, MD, PhD, discusses the role immune checkpoint inhibitors have played in the treatment of triple-negative breast cancer, ongoing efforts to investigate the role of immunotherapy in breast cancer, and the work Cedars-Sinai is conducting to promote breast cancer awareness.
Superior Survival Benefit With Ramucirumab Plus Pembrolizumab Observed in ICI-Resistant NSCLC
June 3rd 2022The addition of ramucirumab to pembrolizumab elicited significant response among patients with advanced non–small cell lung cancer who experienced disease progression following treatment with PD-1/PD-L1 inhibitors and platinum-based doublet chemotherapy.
Role of Adjuvant Chemoradiation Under Study in Gastric Cancer
May 16th 2021Katelyn M. Atkins, MD, PhD, examines the evolving role of radiotherapy in the treatment of patients with gastric cancer, the subgroups who might derive the most benefit from this approach, and ongoing research efforts that are seeking to address remaining questions with this modality.